Teva Pharmaceutical Industries Ltd. (TEVA) reported $3.98 billion in revenue for the quarter ended March 2026, representing a year-over-year increase of 2.3%. EPS of $0.53 for the same period compares to $0.52 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $3.87 billion, representing a surprise of +2.91%. The company delivered an EPS surprise of +6.53%, with the consensus EPS estimate being $0.50.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Teva Pharmaceutical Industries performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Geographic Revenue- Europe- Other: $76 million versus $67.75 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +52% change. Geographic Revenue- Europe- AJOVY: $76 million versus the two-analyst average estimate of $64.4 million. The reported number represents a year-over-year change of +31%. Geographic Revenue- International Markets- AJOVY: $33 million compared to the $30.75 million average estimate based on two analysts. The reported number represents a change of +17.9% year over year. Geographic Revenue- International Markets- Other: $79 million versus $62.53 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +29.5% change. Revenue- North America- UZEDY: $63 million versus the two-analyst average estimate of $56.75 million. Revenues- International Markets- AUSTEDO: $19 million compared to the $18.75 million average estimate based on two analysts. Geographic Revenue- Europe- COPAXONE: $40 million versus $39.95 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -4.8% change. Geographic Revenue- Europe- Respiratory products: $59 million compared to the $59.2 million average estimate based on two analysts. The reported number represents a change of +7.3% year over year. Geographic Revenue- International Markets- Generic products: $386 million versus $468 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -17.5% change. Geographic Revenue- International Markets- COPAXONE: $6 million versus $6.25 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -40% change. Geographic Revenue- Europe- Generic products: $1.09 billion versus the two-analyst average estimate of $1.09 billion. The reported number represents a year-over-year change of +10.1%. Geographic Revenue- United States: $1.53 billion compared to the $1.81 billion average estimate based on two analysts. The reported number represents a change of -19.7% year over year.View all Key Company Metrics for Teva Pharmaceutical Industries here>>>
Shares of Teva Pharmaceutical Industries have returned +5% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Teva Pharmaceutical Industries Ltd. (TEVA): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).